Focus Day

Tuesday June 8 2021

9:30 am Online Check-in & Virtual Coffee

Fundamental TCR Biology Focus Day

9:55 am Chair’s Opening Remark

10:00 am Identifying TCR Specificity and Cross-Reactivity

  • Leah Sibener Co-founder, Head of Therapeutic Discovery, 3T Biosciences

Synopsis

• Comprehensively profiling peptide HLAs bound by TCRs using high diversitiy pHLA Libraries (3T-TRACE)
• Profiling peptide MHCs of clinical TCRs: an opportunity to improve safety whilst maintaining anti-tumor activity
• Selecting lead TCRs using bioinformatics, yeast display & in vitro assays to measure TCR activity & specificity

10:30 am Break Out Audience Discussion: Exploring the Importance of Target Binding Affinity and Avidity for Determining TCR-T Function

  • Leah Sibener Co-founder, Head of Therapeutic Discovery, 3T Biosciences

Synopsis

  • Discussing how the binding strength between a TCR and ligand influences the downstream function of the cell
  • Addressing how high affinity TCRs can negatively impact the function of the cell
  • Predicting optimal TCR-T function by measuring cell avidity
  • Improving surface levels of expression of TCRs

10:50 am Engineering T cells to Overcome Inhibitory Obstacles and Engage the Endogenous Immune Response

  • Shannon Oda Assistant Professor, Seattle Children’s Research Institute & University of Washington

Synopsis

  • Synthetic proteins can be engineered to deliver strong costimulatory signals
  • Therapy with TCR-T cells armored with synthetic proteins results in altered endogenous immunity

11:20 am Break Out Audience Discussion: Investigating the Potential of Genetic Engineering to Address T Cell Exhaustion

  • Shannon Oda Assistant Professor, Seattle Children’s Research Institute & University of Washington

Synopsis

  • Modulating the tumor microenvironment
  • Preventing programmed T cell exhaustion
  • Enhancing tumor recognition and potentiating type I interferon responses
  • Combining epigenetic approaches to enhance immunotherapy

11:40 am Morning Break

12:10 pm Genetic Engineering of T cells to Target Neoantigens in Solid Tumors

Synopsis

  • Non-viral gene transfer such as the Sleeping Beauty system can be used to express neoantigen-specific TCRs
  • T cells can be engineered to target public neoantigens shared between tumors and patients such as KRAS and TP53
  • T cells can be engineered to target private neoantigens unique to tumors and patients

12:40 pm Break Out Audience Discussion

Synopsis

  • How do we enhance receptor-target interactions to develop safe and efficacious TCR products?
  • Overcoming T Cell exhaustion to enhance persistence in vivo
  • Exploring gamma delta T cells as an avenue to circumvent safety concerns and maintain efficacy
  • Investigating the action of gamma delta 1 receptor recognition

1:00 pm Lunch

2:00 pm Mastermind Session: Looking Beyond HLA2 to Reach Wider Patient Populations

  • Erika Von Euw Director, Translational Research, T-Cure Biosciences Inc
  • Leah Sibener Co-founder, Head of Therapeutic Discovery, 3T Biosciences
  • Shannon Oda Assistant Professor, Seattle Children’s Research Institute & University of Washington

Synopsis

  • How do we address broader population needs with regards to cell therapies?
  • Discussing how to address patient needs beyond the HLA2 type

2:30 pm Chair’s closing Remarks & Take Home Messages